Advertisement
CytomX Therapeutics, Inc. (6C1.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Follow
At close: 05:23PM CET
| Previous Close | 0.8530 |
| Open | 0.8280 |
| Bid | 0.9115 x 200000 |
| Ask | 0.9320 x 200000 |
| Day's Range | 0.8280 - 0.8870 |
| 52 Week Range | 0.7825 - 4.4020 |
| Volume | |
| Avg. Volume | 297 |
| Market Cap | 69.416M |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | 5.91 |
| EPS (TTM) | 0.1500 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ZacksJAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer
Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.
- Zacks
Grifols' Board Rejects Brookfield's Buyout Offer, Stock Down 8%
Per GRFS, Brookfield's offer to buy its entire outstanding share capital for 6.45 billion euros significantly undervalues GRFS' prospects and long-term potential.
Advertisement
Advertisement
Advertisement
© 2024 Yahoo. All rights reserved.